| Species |
Human |
| Protein Construction |
HLA-A*02:01&B2M&HIV Gag (SLYNTVATL) Monomer [Gly25-Thr305 (HLA-A*02:01), Ile21-Met119 (B2M) and SLYNTVATL peptide]
Accession # A0A140T913(HLA-A*02:01)&P61769(B2M)&SLYNTVATL |
His |
Avi |
| N-term |
|
C-term |
|
| Purity |
> 95% as determined by BisTris PAGE
> 95% as determined by HPLC |
| Endotoxin Level |
Less than 1EU per μg by the LAL method. |
| Expression System |
HEK293 |
| Theoretical Molecular Weight |
50.39 kDa |
| Apparent Molecular Weight |
Due to glycosylation, the protein migrates to 52-65 kDa based on Bis-Tris PAGE result. |
| Formulation |
Lyophilized from 0.22 μm filtered solution in PBS (pH 7.4). |
| Reconstitution |
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. |
| Storage & Stability |
Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
| Target Background |
Gag is the HIV structural precursor protein which is cleaved by viral protease to produce mature infectious viruses. Gag is a polyprotein composed of MA (matrix), CA (capsid), SP1, NC (nucleocapsid), SP2 and p6 domains. The immunodominant HLA-A2-restricted Gag epitope, SLYNTVATL (SL9), is considered to be a poor immunogen because reactivity to it is rare in acute infection despite its paradoxical dominance in patients with chronic infection. |
| Synonyms |
HIV; HIV Gag; SLYNTVATL |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
